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Objectives: We aimed to measure the vasodilating effects of vitamin C on the radial
arteries of healthy subjects and to assess whether vitamin C is superior in this regard
to diltiazem, a commonly used vasodilator in coronary artery bypass using radial
conduits.
Methods: In a case-control study (study 1) oral single-dose vitamin C (2 g) was
given to 15 healthy nonsmokers and 15 matched otherwise healthy smokers. In a
randomized double-blind study (study 2) oral single-dose vitamin C (2 g, n  15)
and diltiazem (180 mg, n  15) were compared in preoperative patients with
coronary artery disease. We examined the dilation of the radial artery with high-
resolution ultrasonography and measurement of the lumen surface and color Dopp-
ler images of the nondominant radial artery just before and 2 hours after drug
administration.
Results: In study 1 both smokers and nonsmokers showed a significant increase in
the lumen surface at 2 hours compared with at baseline (P  .001 and P  .013,
respectively). The increase was larger in smokers (median, 37.5% vs 14.3%; P 
.004). In study 2 both groups showed statistically significant increases in the lumen
surface at 2 hours compared with at baseline (P  .001 and P  .008 for vitamin
C and diltiazem, respectively). Vitamin C achieved a larger increase than diltiazem
(median, 33.3% vs 18.2%; P  .016). In multivariate modeling the increase in
lumen surface was independently predicted by use of vitamin C over diltiazem
(21.2%, P  .007), diabetes mellitus (14.5%, P  .085), increased cholesterol
(26.2%, P  .001), and smoking history (20.8%, P  .017).
Conclusions: Vitamin C is a potent acute vasodilator in both smokers and nonsmok-
ers and is superior to diltiazem in preoperative coronary patients who need protec-
tion from vasospasm of the radial conduit.
The radial artery is increasingly used as a conduit for coronary arterybypass grafting because of reports of long-term patency, accessibil-ity, and encouraging midterm results.1-3 Calcium-channel antago-nists, in particular diltiazem, or other vasodilators are used to preventperioperative spasm of the graft.4-6 The choice of a potent vasodi-lator with minimal side effects appears to be an important parameter
in ensuring the success of radial artery conduits.
Human coronary and peripheral arteries display abnormal endothelial function
and loss of endothelium-dependent vasodilation in the presence of overt coronary
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artery disease or coronary risk factors.7-9 Ascorbic acid, or
vitamin C, the main water-soluble antioxidant in human
plasma10 has been shown to reverse endothelial dysfunction
in patients with ischemic heart disease.11,12 It has also been
shown to improve endothelial dysfunction in smokers13-15
and patients with diabetes,16 hypercholesterolemia,17 and
hypertension,18 although not in a consistent manner.19,20 It is
not known whether, given these observations, vitamin C
could be used instead of calcium-channel blockers as a
vasodilator in coronary surgery patients receiving radial
artery conduits.
Vitamin C was studied in 2 groups of healthy volunteers
with and without a history of smoking. Subsequently, in a
randomized double-blind study vitamin C was compared
with diltiazem in patients with coronary artery disease, as




A total of 30 healthy subjects were enrolled in a case-control study
evaluating the effects of vitamin C in smokers (n  15) versus
nonsmokers (n  15, study 1). Exclusion criteria included known
cardiovascular disease or the presence of any known coronary risk
factors (other than smoking and family history). Subjects in the 2
groups were frequency matched for age. Subjects in both groups
received vitamin C orally (2 g), and the effect on the radial artery
was assessed 2 hours later by an evaluator who was blinded to the
smoking status of the subject. The vitamin C dose was selected
because it has been used in previous studies21 and is known to
achieve 2.5-fold increases of plasma ascorbic acid in 2 hours.12
A total of 30 preoperative subjects with coronary artery disease
who had been admitted to the Department of Cardiothoracic Sur-
gery of the University of Ioannina were enrolled in a randomized,
double-blind, parallel-arm trial comparing single-dose oral vitamin
C (2 g) with oral diltiazem (180 mg, study 2). The effect of each
drug on the radial artery was similarly assessed 2 hours after drug
administration by a blinded evaluator. The randomization was
performed by using a computer-generated code, and allocation
concealment was ensured.
For both studies, all subjects had to refrain from smoking for at
least 3 hours before the study to minimize any relevant effect of
acute smoking. In addition, all subjects were instructed to refrain
from the intake of caffeine-containing beverages within 24 hours
before administration of the drug. No patients were receiving any
vitamins. The collected information on each subject included de-
mographics, as well as data on potential cardiovascular risk factors
for the subjects enrolled in the randomized trial. Both studies
received approval, and all subjects were enrolled after providing
informed consent according to the hospital’s ethics committee. No
patients withdrew after providing informed consent.
Radial Artery Measurements
High-resolution ultrasound measurements and color Doppler im-
ages were taken by using an ultrasound device (color Doppler
Acuson 128 XP/10 with 7-MHz linear transducer), and records of
the lumen surface of the radial artery (nondominant) before the
drug administration were followed by using a measurement 2
hours later (Figure 1). All lumen surface areas (derived from the
estimated lumen diameter) are expressed in square millimeters.
The measurements were performed by 2 independent observers
who were blinded as to the group to which the individual belonged.
For each patient, optimal radial artery images were obtained be-
tween 2 and 5 cm above the radial styloid. This location was
marked, and all subsequent images were obtained at the same
location. In our study, the interobserver variability for the repeated
measurements of resting radial artery diameter was 0.04  0.02
mm. The intraobserver variability for the repeated measurements
of resting radial artery diameter was 0.03  0.02 mm.
Statistical Methods
Both the case-control and randomized studies were designed to
have 80% power (  .20) to detect a difference of 20% between
the compared groups at an  value of .05, assuming that the SD of
the percentage changes in the artery lumen surface seen at 2 hours
would be approximately 15%. With these assumptions, we esti-
mated that 15 subjects per group would be needed.
Comparisons of groups were performed with the t test and
nonparametric Mann-Whitney U test for continuous variables and
the Fisher exact test for discrete variables, as appropriate. Pre-post
comparisons with paired observations were analyzed by using the
Wilcoxon test. Linear regression models were built with least-
squares methods by using all variables and also with a backward
elimination approach, starting with all variables that were signif-
icant (P  .05) in univariate relationships and eliminating vari-
ables with P values of greater than .05 in a stepwise fashion. Given
the limited sample size, multivariate models should be viewed
cautiously, but they are useful in further validating the unadjusted
results. All analyses were conducted with SPSS 10.0 software
(SPSS Inc, Chicago, Ill), and all P values are 2-tailed.
Results
Characteristics of Subjects
Tables 1 and 2 summarize key characteristics of the subjects
in the case-control study and of the patients in the random-
ized controlled trial. As shown, there were no significant
differences between the compared groups for either of the 2
comparisons. High cholesterol, diabetes, and hypertension
were relatively common among the preoperative patients
with coronary artery disease who were enrolled in the
randomized trial. Left ventricular ejection fractions were
similar, and the use of -blockade was not different in the
2 groups.
Case-control Study: Evaluation of Vitamin C in
Smokers Versus Nonsmokers
Both smokers and nonsmokers showed a statistically sig-
nificant increase in the radial artery lumen surface at 2 hours
compared with at baseline (P  .001 and P  .013, respec-
tively, Wilcoxon test). Nonsmokers showed a median in-
crease of 14.3% (interquartile range [IQR], 0%-28.6%;
mean, 16.0%), whereas the respective increase in smokers
was 37.5% (IQR, 25.0%-57.1%; mean, 42.4%). The in-
crease in the lumen surface was significantly larger in the
group of smokers (Figure 2). After adjusting for age in a
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mutlivariate model, smokers still had a larger increase
(30.4%, P  .0016), whereas age had a marginal influ-
ence, with decreasing response in older subjects (0.60%
per year, P  .092).
Randomized Study of Vitamin C Versus Diltiazem
Both patients in the vitamin C group and patients in the
diltiazem group showed statistically significant increases of
the radial artery lumen surface at 2 hours compared with
baseline values (P  .001 and P  .008, respectively,
Wilcoxon test). Patients receiving vitamin C showed a me-
dian increase of 33.3% (IQR, 14.3%-45.5%; mean, 35.4%),
whereas the respective median increase in the diltiazem
group was only 18.2% (IQR, 0%-22.2%; mean, 16.9%). The
difference was statistically significant (Figure 3).
In an adjusted analysis considering age, sex, systolic and
Figure 1. High-resolution ultrasound and color Doppler images in a preoperative patient with coronary artery
disease before (right images, lumen surface of the radial artery, 10 mm2) and 2 hours after the oral administration
of 2 g of vitamin C (left images, lumen surface of the radial artery, 14 mm2).
TABLE 1. Summary of the key characteristics of the subjects in the case-control study
Case-control comparison in healthy adults
P valueNonsmokers Smokers
Age, median (IQR) 29 (25-34) 31 (29-46) .17
Male/female sex 9/6 8/7 .46
History of smoking 0 15 –
High cholesterol 0 0 –
Diabetes mellitus 0 0 –
Diastolic blood pressure, mean (SD) Normal Normal –
Systolic blood pressure, mean (SD) Normal Normal –
Baseline surface in mm2, median (IQR) 9 (8-13) 9 (8-10) .13
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diastolic pressure, the presence of diabetes mellitus, high
cholesterol levels, and history of smoking, vitamin C still
resulted in a statistically better response than diltiazem
(22.4%, P  .009). A backward elimination model start-
ing from these variables showed that the percentage re-
sponse was independently predicted by the use of vitamin C
over diltiazem (21.2%, P  .007), diabetes mellitus
(14.5%, P  .085), high cholesterol levels (26.2%, P 
.001), and a history of smoking (20.8%, P  .017). Age,
sex, and blood pressure were not retained as independent
predictors in this multivariate model. There was no strong
evidence of interaction effects between the retained inde-
pendent predictors.
Safety
There were 2 patients with asymptomatic modest decreases
in blood pressure and heart rate in the diltiazem group. No
other side effects were observed.
Figure 2. Baseline and 2-hour values of radial artery surface area
in smokers and nonsmokers. Given a similar baseline value,
smokers typically achieve larger vasodilatation at 2 hours (P 
.005 by t test and P  .004, Mann-Whitney U test). Not shown is
one outlier in the nonsmoker group. The regression lines are fit
separately to each group (2-hour value  2.9  0.86  baseline
value for the nonsmokers and 7.9  0.50  baseline value for
smokers).
Figure 3. Baseline and 2-hour values of radial artery surface area
in the diltiazem and vitamin C groups. Given a similar baseline
value, patients receiving vitamin C typically achieve larger va-
sodilatation at 2 hours (P  .043 by t test and P  .016, Mann-
Whitney U test). The regression lines are fit separately to each
group (2-hour value 1.0 1.25 baseline value for the vitamin
C group and 3.7  0.78  baseline value for the diltiazem group).
TABLE 2. Summary of the key characteristics of the patients in the randomized controlled study
Randomized study in patients with CAD
P valueVitamin C Diltiazem
Age, median (IQR) 72 (67-74) 69 (65-73) .27
Male/female sex 10/5 9/6 .71
History of smoking 10 8 .46
High cholesterol 7 9 .47
Diabetes mellitus 5 7 .46
Diastolic blood pressure, mean (SD) 86 (7) 89 (8) .29
Systolic blood pressure, mean (SD) 141 (17) 149 (19) .25
Baseline surface in mm2, median (IQR) 9 (8-11) 10 (9-12) .30
Left ventricular ejection fraction (%), mean (SD) 50 (13) 52 (11) .50
No. of diseased coronary arteries (median) 2 2 1.00
Use of  blockade (no. of patients) 4 5 .70
Use of nitrates 0 0 1.00
Use of angiotensin-converting enzyme inhibitors 7 8 .72
Use of calcium-channel blockers 0 0 1.00
CAD, Coronary artery disease.
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The vasodilator of choice in radial conduits is still a matter
of controversy.22-25 Neurohormonal activation during coro-
nary revascularization stimulates the release of bioactive
peptides and catecholamines, both of which might contrib-
ute to early radial artery vasospasm.22 Endothelin and nor-
epinephrine cause vascular smooth muscle contraction
through the activation of calcium channels.22 This engages
the contractile apparatus, resulting in vasoconstriction.
Calcium-channel antagonists are selective vasodilators
that inhibit the voltage-dependent calcium channel in hu-
man arteries;23 they are less effective at inhibiting vascular
contraction mediated by receptor mechanisms.23
Diltiazem is a 1,5-benzothiazepine that binds to the a1c
subunit of the L-type calcium channel, the main pore-form-
ing unit of the channel.25 Blockage of L-type calcium chan-
nels in vascular tissues results in relaxation of vascular
smooth muscle and vasodilation.25 L-Type blockade in the
heart, however, results in negative inotropic and chrono-
tropic effect that induces bradycardia, particularly when
used in combination with -blockers,23 a cornerstone in the
management of ischemic heart failure. It is also notorious
for the frequent need to modify its dosage or discontinue its
administration because of hypotension perioperatively.
Moreover, use of diltiazem does not completely eliminate
spasm and has been reported to be less effective than other
vasodilators, such as nitroglycerin.24,25
Vitamin C (ascorbate), an antioxidant factor, improves
defective endothelial function. This has been attributed to
an enhancement of the synthesis or prevention of the break-
down of nitric oxide.21 Vitamin C–induced decreases in
low-density lipoprotein oxidation, scavenging of intracellu-
lar superoxide, release of nitric oxide from circulating or
tissue S-nitrosothiols, direct reduction of nitride to nitric
oxide, and activation of either endothelial nitric oxide syn-
thetase or smooth muscle guanylate cyclase might all be
implicated in the ability of ascorbate to preserve nitric
oxide.21,26,27
Smoking has a direct toxic effect on human endothelial
cells.14 The gas phase of cigarette smoke contains free
radicals and pro-oxidants, and the particulate phase contains
high concentrations of lipophilic quinones, which can form
the highly reactive OH. radical.14 In addition, superoxide
anion, which directly originates from smoke, results in the
formation of peroxynitrite anion (ONOO), which reduces
the vasoactivate level of nitric oxide.14 In our case-control
study vitamin C was able to achieve substantial vasodilation
of the radial artery among healthy young adults, and the
effect was more prominent among smokers. This suggests
that vitamin C might be even more useful among smokers,
in whom the underlying vasoconstrictive effects might be
more prominent, and the mechanism of action of vitamin C
might share a common pathway counterbalancing the bio-
logic effects of chronic smoking. Interestingly, smokers are
known to have lower plasma28 and tissue15 vitamin C levels
than nonsmokers.
Vitamin C has a potent acute vasodilating effect on the
radial artery, and the effect is more prominent among smok-
ers. On the basis of this (first to our knowledge) double-
blind randomized comparison, we demonstrated that a sin-
gle oral dose of vitamin C achieves better vasodilation of
the radial artery than diltiazem in preoperative coronary
patients. In the multivariate analysis of the data from the
randomized trial, vitamin C was superior to diltiazem in
achieving radial artery vasodilation, even when all the other
key risk factors that seem to affect endothelial dysfunction
(including smoking, hypertension, diabetes, and hypercho-
lesterolemia) were taken into account.
Study Limitations
The beneficial effects of vitamin C might not necessarily
translate into efficacy during the perioperative manipula-
tions after an acute surgical, metabolic, and pharmacologic
assault. Furthermore, in healthy young smokers vitamin C
has been shown not to have sustainable, long-term effects
on endothelial function, despite sustained increase of
plasma ascorbate levels,20 and although vitamin C improves
endothelial dysfunction, there is no proved relationship be-
tween baseline ascorbic acid concentration and baseline
endothelial function.12 Our results, however, suggest a po-
tential role for this substance in the management of patients
receiving radial artery grafts. This role would have to be
further delineated against other available vasodilation op-
tions in this setting. For example, in addition to calcium-
channel blockers, nitroglycerin has also shown significant
efficacy for preventing coronary bypass conduit spasm,24,25
and a combination of calcium-channel blockers with nitro-
glycerin29 might be even more potent. However, recent
evidence of unchanged coronary vascular resistance during
postoperative nitroglycerin administration casts doubt on
such use.30 Future studies should compare vitamin C against
such combinations.
Conclusion
The results of the present study provide evidence that vita-
min C is a potent vasodilator in healthy subjects, particu-
larly smokers. In addition, it is a superior acute vasodilating
agent in vivo compared with diltiazem in ischemic patients
awaiting cardiac surgery. This pilot study should justify a
perioperative trial to evaluate the vasodilating effect of
vitamin C on radial artery conduits during coronary revas-
cularization.
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